Evotec’s biologics manufacturing unit, dubbed Just – Evotec Biologics, has expanded its multiyear biosimilar deal with Sandoz that the partners initially inked in May 2023.
As part of the pact, Sandoz is leveraging Just – Evotec Biologics’ drug substance development platform and manufacturing technology. Previously, Sandoz said it would use the tech to expand its pipeline of biosimilars from 15 to about 24 candidates.
Under the new expansion, Sandoz has secured capacity for "long-term commercial supply" of biosimilar drugs, according to a July 8 joint release from the companies.
Sandoz previously paid Just – Evotec Biologics a "double-digit-million" upfront payment in the collaboration, with milestones taking the deal value up to a potential $640 million.
In the updated release, Just – Evotec said it expects "appropriate remuneration" following early scientific validation, with additional money coming in as certain development milestones are reached into 2025.
“We are thrilled to expand our partnership with Sandoz, building on the successes we’ve achieved since the initial launch,” Matthias Evers, Ph.D., Evotec’s chief executive, said in a statement. “Introducing additional molecules has the potential to enhance access for millions of patients, while commercial manufacturing from Toulouse will ensure the long-term supply of Sandoz’ biosimilar portfolio.”
The German biotech-CRO hybrid operates two J.POD biologics manufacturing facilities located in Toulouse, France, and Redmond, Washington.
Sandoz, for its part, was spun off from Novartis in 2023. In recent years, Sandoz has been working to grow its biosimilars footprint with investments at its Holzkirchen, Germany, site and plans for a $400 million plant in Slovenia.